Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Gram-negative resistance: can we combat the coming of a new "Red Plague"?

Looke DF, Gottlieb T, Jones CA, Paterson DL.

Med J Aust. 2013 Mar 18;198(5):243-4. No abstract available.

PMID:
23496385
2.

Call for global action to halt the superbug.

Ghafur A.

Med J Aust. 2013 Mar 18;198(5):251. No abstract available.

PMID:
23496388
3.

New Delhi metallo-beta-lactamase-producing enterobacteriaceae in an Australian child who had not travelled overseas.

Blyth CC, Pereira L, Goire N.

Med J Aust. 2014 Apr 21;200(7):386. No abstract available.

PMID:
24794661
4.

Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?

Apisarnthanarak A, Hsu LY, Khawcharoenporn T, Mundy LM.

Expert Rev Anti Infect Ther. 2013 Feb;11(2):147-57. doi: 10.1586/eri.12.164.

PMID:
23409821
5.

Antibiotic rotation and development of gram-negative antibiotic resistance.

van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJ.

Am J Respir Crit Care Med. 2005 Mar 1;171(5):480-7. Epub 2004 Oct 29.

PMID:
15516540
6.

Resistant gram-negative bacilli: A neglected healthcare crisis?

Lautenbach E, Polk RE.

Am J Health Syst Pharm. 2007 Dec 1;64(23 Suppl 14):S3-21; quiz S22-4.

PMID:
18029939
7.

Does antimicrobial use increase the rate of antimicrobial resistance? A one year experience.

Gedik H.

Indian J Med Microbiol. 2012 Apr-Jun;30(2):198-202. doi: 10.4103/0255-0857.96692.

8.

Epidemiology, control and treatment of multiresistant gram-negative rods.

Wiedemann B.

Drugs. 1996;52 Suppl 2:95-100; discussion 100-2. Review. No abstract available.

PMID:
8869845
9.

Multiresistant Gram-negative infections: a global perspective.

Ho J, Tambyah PA, Paterson DL.

Curr Opin Infect Dis. 2010 Dec;23(6):546-53. doi: 10.1097/QCO.0b013e32833f0d3e. Review.

PMID:
20802331
10.

Editorial: Resistance in gram-negative pathogens: a threat to global health.

Hanson ND.

Curr Pharm Des. 2013;19(2):163. No abstract available.

PMID:
22920832
11.

Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients.

Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, Fraser VJ, Fridkin SK.

Crit Care Med. 2004 Dec;32(12):2450-6.

PMID:
15599150
12.

[Antibiotic therapy by suppurative diseases of the abdominal cavity and soft tissues].

Sazhin VP, Bodrova NG, Klimov DE, Iurishchev VA, Avdovenko AL, Sazhin IV.

Khirurgiia (Mosk). 2010;(6):4-9. Russian.

PMID:
20559216
13.

Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections.

Akinci E, Colpan A, Bodur H, Balaban N, Erbay A.

J Hosp Infect. 2005 Apr;59(4):317-23.

PMID:
15749320
14.

Intrathecal use of colistin.

Vasen W, Desmery P, Ilutovich S, Di Martino A.

J Clin Microbiol. 2000 Sep;38(9):3523. No abstract available.

15.

Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.

Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou H.

Clin Microbiol Infect. 2011 Nov;17(11):E9-E11. doi: 10.1111/j.1469-0691.2011.03649.x. Epub 2011 Sep 21.

16.

Intra-abdominal infections: do we need to change our antibiotic coverage in this era of Gram negative resistance?

Gopalakrishnan R.

J Assoc Physicians India. 2011 May;59:285. No abstract available.

PMID:
21751603
17.
18.

Impact of a hospital-wide antibiotic restriction policy program on the resistance rates of nosocomial Gram-negative bacteria.

Antoniadou A, Kanellakopoulou K, Kanellopoulou M, Polemis M, Koratzanis G, Papademetriou E, Poulakou G, Giannitsioti E, Souli M, Vatopoulos A, Giamarellou H.

Scand J Infect Dis. 2013 Jun;45(6):438-45. doi: 10.3109/00365548.2012.760845. Epub 2013 Jan 22.

PMID:
23336730
19.

Gram-negative antibiotic resistance: there is a price to pay.

Slama TG.

Crit Care. 2008;12 Suppl 4:S4. doi: 10.1186/cc6820. Epub 2008 May 21. Review.

20.

Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin.

Valour F, Dutronc H, Dinh A, Cazorla C, Pavèse P, Lesens O, Uçkay I, Chidiac C, Ferry T; Colistin BJIs Study Group.

Int J Antimicrob Agents. 2013 Feb;41(2):197-9. doi: 10.1016/j.ijantimicag.2012.09.016. Epub 2012 Nov 10. No abstract available.

PMID:
23146203
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk